**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Agathe COSTE, Pfizer Rare Diseases Medical Advisor, Paris, France

**Main Body of the Abstract**
Objective:
We aimed to described patient profiles and diagnosis pathway of hereditary transthyretin amyloidosis (ATTRv) cardiomyopathy (CM) and wild-type transthyretin amyloidosis (ATTRwt) CM in French expert centers between 2009 and 2019.
Methods:
This was a non-interventional descriptive retrospective multi-center national study involving thirteen French hospitals. Patient with an history of ATTR, ≥18 years were included, and their medical chart were reviewed to identify clinical manifestations, diagnostic methods and targeted treatment.
Results:
Three hundred thirty-three patients were analyzed (177 ATTRwt-CM, 117 ATTRv-mixed, 39 ATTRv-CM). Before diagnosis one-fourth of patients had cardiac decompensation, and a fifth had a pacemaker. ATTRwt patients were older than ATTRv patients (80.1 vs. 64.2 years), had a higher prevalence of hypertension (51.4 vs. 35.3%), and a higher prevalence of arrhythmias (45.8 vs. 28.3%). There were no differences in disease severity according to New York Heart Association classification. ATTRv patients had more neurological symptoms than ATTRwt patients. Biopsy was performed on nearly 90% of patients, most of which were positive. Salivary glands and heart tissue were the most common biopsy sites.
Conclusion:
This study on real-world clinical ATTR cases further elucidated the characteristics and diagnostic approach among patients with ATTR CM.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Agathe COSTE, Pfizer Rare Diseases Medical Advisor, Paris, France

**Main Body of the Abstract**
**Objective:**
We aimed to described patient profiles and diagnosis pathway of hereditary transthyretin amyloidosis (ATTRv) cardiomyopathy (CM) and wild-type transthyretin amyloidosis (ATTRwt) CM in French expert centers between 2009 and 2019.
**Methods:**
This was a non-interventional descriptive retrospective multi-center national study involving thirteen French hospitals. Patient with an history of ATTR, ≥18 years were included, and their medical chart were reviewed to identify clinical manifestations, diagnostic methods and targeted treatment.
**Results:**
Three hundred thirty-three patients were analyzed (177 ATTRwt-CM, 117 ATTRv-mixed, 39 ATTRv-CM). Before diagnosis one-fourth of patients had cardiac decompensation, and a fifth had a pacemaker. ATTRwt patients were older than ATTRv patients (80.1 vs. 64.2 years), had a higher prevalence of hypertension (51.4 vs. 35.3%), and a higher prevalence of arrhythmias (45.8 vs. 28.3%). There were no differences in disease severity according to New York Heart Association classification. ATTRv patients had more neurological symptoms than ATTRwt patients. Biopsy was performed on nearly 90% of patients, most of which were positive. Salivary glands and heart tissue were the most common biopsy sites.
**Conclusion:**
This study on real-world clinical ATTR cases further elucidated the characteristics and diagnostic approach among patients with ATTR CM.



Transthyretin amyloid cardiomyopathy in France: A medical chart multi-center study (333 patients) PB63 (#148)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.